TVGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Tevogen Bio Holdings Inc (TVGN) is not a strong buy at this time for a beginner investor with a long-term strategy. While there are potential positive catalysts from the company's strategic initiatives, the lack of financial growth, insider selling, and absence of strong technical or trading signals make it prudent to hold off on investing until more favorable conditions emerge.
The MACD is positive and expanding, indicating a potential upward momentum. However, the RSI is neutral at 58.287, and the moving averages are converging, suggesting no clear trend. The pre-market price is $0.288, down -0.48%, with key support at $0.254 and resistance at $0.301.
Tevogen's potential acquisition of Sciometrix and integration of its digital care management platform with Tevogen.AI could enhance revenue-generating capabilities and improve patient care. Sciometrix's strong position in the digital healthcare sector adds credibility to this initiative.
Insider selling has increased significantly by 140.46% over the last month, which could indicate a lack of confidence in the company's near-term prospects. Additionally, the company's financial performance shows no revenue growth and a net income decline of -0.80% YoY.
In Q3 2025, the company reported no revenue growth (0% YoY), a net income decline of -0.80% YoY to -$5,862,428, and an EPS of -0.03. Gross margin remains at 0%, indicating no profitability.
No data available for analyst ratings or price target changes.
